Anastrozole – A New Generation in Aromatase Inhibition: Clinical Pharmacology

Oncology (Switzerland)

Volumn 54, Issue 2, 1997, Pages 11-14

  Dowsett, M ^a   Lonning, P E ^b  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

Anastrozole; Aromatase inhibition; Oestrogen suppression

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE; ESTROGEN; ESTRONE SULFATE; FADROZOLE; FORMESTANE; LETROZOLE; PYRIDOGLUTETHIMIDE;

BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG SELECTIVITY; DRUG TOXICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ESTROGEN BLOOD LEVEL; HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; ENZYME INHIBITORS; ESTROGENS; FEMALE; HUMANS; NITRILES; TRIAZOLES;

EID: 0030725997     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000227750     Document Type: Article

References (12)

1. Muss HB: Endocrine therapy for advanced breast cancer: A review. Breast Cancer Res Treat 1992;21:15-26.
2. Goss PE, Gwyn KMEH: Current perspectives on aromatase inhibitors in breast cancer. J Clin Oncol 1994:12:2460-2470.
3. Jacobs S, MacNeill F, Lonning P, Dowsett M, Jones A, Powles TJ: Aromatase activity, serum oestradiol and their correlation with demographic indices. J Steroid Biochem Mol Biol 1992;41:769-771.
4. Jacobs S, Lonning PE, Haynes B, Griggs L, Dowsett M: Measurement of aromatisation by a urine technique suitable for the evaluation of aromatase inhibitors in vivo. J Enzym Inhib 1991;4:315-325.
5. Dowsett M, Jones A, Johnston SRD, Jacobs S, Trunet P, Smith IE: In vivo measurement of aromatase inhibition by letrozole (CGS 20267) in postmenopausal patients with breast cancer. Clin Cancer Res 1995;1:1511-1515.
6. Lonning PE, Ekse D: A sensitive assay for measurement of plasma oestrone sulphate in patients on treatment with aromatase inhibitors. J Steroid Biochcm Mol Biol 1995;55:409-412.
7. Dowsett M, Cunningham DC, Stein RC, Evans S, Dehennin L. Hedley A, Coombes RC: Dose-related endocrine effects and pharmacokinetics of oral and intramuscular 4-hydroxyandrostcne-dione in postmenopausal breast cancer patients. Cancer Res 1989;49:1306-1312.
8. Lonning PE, Hellc SI, Johannessen DC, Adler-creutz H, Lien EA, Tally M, Ekse D. Fotsis T, Anker GB, Hall K: Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in postmenopausal breast cancer patients. Clin Endocrinol 1995;42:23-30.
9. Geisler J, King N, Dowsett M, Ottestad L, Lundgren S, Walton P, Kormeset PO, Lonning PE: Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. Br J Cancer 1996:74:1286-1291.
10. MacNeill FA, Jones AL, Jacobs S, Lonning PE, Powles TJ, Dowsett M: The influence of ami-noglutethimidc and its analogue rogletimide on peripheral aromatisation in breast cancer. Br J Cancer 1992;66:692-697.
11. Dowsett M, Stein RC, Mehta A, Coombes RC: Potency and selectivity of the non-steroidal aromatase inhibitor CGS 16949A in postmenopausal breast cancer patients. Clin Endocrinol 0x0 1990;32:623-634.
12. Lonning PE, Jacobs S, Jones A, Haynes B, Powles T, Dowsett M: The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. Br J Cancer 1991;63:789-793.